Improve liver health by redefining alcohol dependency behaviour
AlcoChange® is a personalised behaviour change digital therapeutic program that can help with reducing and abstaining from alcohol with real-time digital interventions.
AlcoChange® is a personalised behaviour change digital therapeutic program that can help with reducing and abstaining from alcohol with real-time digital interventions.
Continued alcohol use is the single largest determinant of the prognosis of ARLD patients, with a 50% mortality rate within 3 years.
There is no effective pharmacological therapy to ensure abstinence or reduction in alcohol use in ARLD patients. The most important element in ensuring that an ARLD patient does not deteriorate involves cutting down or eliminating alcohol use, ultimately leading to total abstinence. Whilst Alcohol Care Teams exist for this very purpose, they are not a scalable solution and, in reality, only a small proportion of harmful drinkers receive interventions from such teams.
AlcoChange® system, software as a medical device (SaMD), provides an innovative solution to address this problem. At its core, AlcoChange® consists of a smartphone app that communicates with the CyberLiver Platform and connects with an external digital biomarker that enables self-recording of abstinence or alcohol use and provide positive reinforcement. AlcoChange – a novel, patented, UKCA-marked digital therapeutic is developed with feedback from alcohol service users and validated in a pilot study in a clinical setting in the UK.
AlcoChange® intended to reduce alcohol use and maintain abstinence in individuals with established alcohol-related liver disease.
AlcoChange is proven to help people reduce alcohol consumption and work towards abstinence, which is essential in improving liver health
AlcoChange is a patented groundbreaking Digital Therapeutic solution that is designed to help users abstain from or reduce alcohol consumption
AlcoChange was created based on an amalgamation of various behavioural change techniques
AlcoChange brings the science of behaviour change increase abstinence and increase retention in the outpatient treatment program.
Behavioural interventions are personalised and ever-evolving to adapt to the user’s needs
Encourages engagement and participation through regular motivations, nudges and follow-ups
Learn how to identify triggers, break negative behaviours, and develop healthier responses
In hospitals, Alcohol Care Teams (ACTs) work to help high-risk patients with liver disease to abstain from consuming alcohol. However, increasing numbers of patients year-on-year mean ACTs cannot review every patient. AlcoChange could help reduce the number of hospital admissions and deaths associated with alcohol-related liver disease with the help of a behavioural change smartphone app.
AlcoChange has already been shown to have positive benefits in an initial study at the Royal Free Hospital in London. More extensive clinical trials are underway, with one of the studies coordinated by the Southampton Clinical Trials Unit (SCTU). Know more about the AlcoChange Clinical Trial Click here.
If you want to improve your liver health outcome, please check with your healthcare provider whether they offer the AlcoChange prescription therapy. AlcoChange therapy is currently been provided only via your Healthcare provider.
f you are a healthcare provider and would like to partner with us for a clinical trial, please email [email protected].
AlcoChange is a 90 day prescription digital therapeutic.
AlcoChange comes included with the AlcoChange patient app and an optional Digital Breathalyser.
As part of the enrolment and onboarding, you will be guided using the AlcoChange application and breathalyser.
As part of the AlcoChange clinician setup, you will have access to patient details and real-time patient monitoring using an actionable clinician dashboard.
Please contact our support team at [email protected] if you have any technical issues with the AlcoChange app or breathalyser.
Read more on liver health and how CyberLiver helps redefine it with its solutions.
Clinical
Cyberliver Announces Poster Presentation of AlcoChange
Pilot Study at The Liver Meeting 2018
Read More
Clinical
AlcoChange: a smartphone tool to reduce alcohol use and admissions in alcoholic liver disease
Royal Free London NHS Foundation Trust
Read MoreGetting started with AlcoChange
Whether you are a healthcare provider, a clinical trial partner, an ARLD patient or a user who wants to reduce your alcohol consumption and gain access to AlcoChange or support along your journey, we are here to help.
Email us at [email protected]
Customer Support
If you are an already existing customer or have technical or other issues, our experts are ready to help.
Email us at [email protected]